v3.26.3
Commitments and Contingencies (Tables)
 9 Months Ended
Sep. 30, 2026
GlaxoSmithKline LLC [Member]  
Summary of Expenses Incurred by Company

Expenses incurred by the Company related to the GSK License were recorded as follows (in thousands):

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Cost of license and royalty revenues:

 

 

 

 

 

 

 

 

 

 

 

 

Royalties on net sales of Zolgensma and Itvisma

 

$

869

 

 

$

5,709

 

 

$

2,678

 

 

$

13,495

 

Settlement payment

 

 

—

 

 

 

—

 

 

 

10,000

 

 

 

—

 

Other

 

 

—

 

 

 

1

 

 

 

140

 

 

 

244

 

Total cost of license and royalty revenues

 

 

869

 

 

 

5,710

 

 

 

12,818

 

 

 

13,739

 

General and administrative

 

 

(29

)

 

 

30

 

 

 

50

 

 

 

137

 

 

 

$

840

 

 

$

5,740

 

 

$

12,868

 

 

$

13,876